About the Angiosarcoma Session
Angiosarcoma, an uncommon and aggressive cancer originating in blood or lymphatic vessel linings, poses significant challenges in research and treatment. Exploring its multifaceted origins, from genetic mutations to environmental triggers like radiation exposure, drives investigations. While conventional treatments such as surgery, chemotherapy, and radiation remain mainstays, emerging therapies like targeted drugs and immunotherapy offer promising avenues. Yet, due to its rarity, collaborative research endeavors and clinical trials are imperative for unraveling angiosarcoma's complexities and enhancing patient care.
Topics Covered in Angiosarcoma
Radiation-Associated Forms
Scalp & Facial Disease
Endothelial Markers
MYC Amplification
Taxane-Based Chemotherapy
Anti-Angiogenic Therapy
Related Scientific Sessions at CIOC 2027
Why Attend the Angiosarcoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Angiosarcoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Angiosarcoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Angiosarcoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Angiosarcoma Conference 2027 — FAQs
What is the Angiosarcoma track at CIOC 2027?
The Angiosarcoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Angiosarcoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Angiosarcoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Angiosarcoma are all welcome — whether presenting or attending.
Can I present my research in the Angiosarcoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Angiosarcoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Angiosarcoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.